Phantomics signed an MOU with Pamicell to collaborate on research for digital twins in the diagnosis and treatment of cardiovascular diseases using high-dimensional biomarkers. Pamicell, a company developing cardiovascular therapies, will work with Phantomics to discover image biomarkers related to stem cell therapy and develop predictive models based on those biomarkers. The specific goals of the collaboration include discovering image biomarkers related to stem cell therapy efficacy and prognosis, developing predictive models for stem cell therapy efficacy, conducting image analysis research, and providing education and training for researchers. Phantomics specializes in developing AI software for medical imaging analysis and diagnosis, with a focus on quantitative diagnosis methods using AI and big data. In December 2022, Phantomics received approval to sell three types of AI-assisted cardiac MRI analysis software from the US FDA and Korean FDA. Pamicell hopes to discover biomarkers that can predict the therapeutic effects of stem cell therapy for acute myocardial infarction patients based on clinical trial data. Pamicell officials expressed hope that this collaboration would increase the effectiveness of stem cell therapies.